Abstract Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma.We examined whether histone deacetylase inhibition could potentiate the DNA strand cleavage, cytotoxicity as well as the clinical toxicity, and efficacy of KTN in melanoma. Experimental Design: Apoptosis, COMET, and xenograft experiments were carried out as described previously. A phase I/II trial of valproic acid (VPA) and KTN was conducted in patients with stage IV melanoma, with any number of prior therapies, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Results: VPA pretreatment potentiated KTN-induced apoptosis in multiple melanoma cell lines and in mouse A375 xenografts. VPA increased KTN-induced DNA strand breaks. In the phase I/II trial, 39 patients were entered, with 37 evaluable for toxicity and 33 evaluable for response. Somnolence was the dose-limiting toxicity.The maximum tolerated dose forVPA was 75 mg/kg/d; at maximum tolerated dose, serumVPA was f200 Ag/mL (1.28 mmol/L). At the dose expansion cohort, 47% (7 of 15) of patients had stable disease; median overall survival and time to progression were 32.8 and10.2 weeks, respectively. Histone hyperacetylation was observed in peripheral blood mononuclear cells at maximum tolerated dose. Conclusion: VPA potentiates KTN-induced DNA strand breaks and cytotoxicity. VPA can be combined at 75 mg/kg/d for 5 days with full-dose KTN without overlapping toxicities. In metastatic poor prognosis melanoma, this combination is associated with disease stabilization in 47% of patients. Further testing of this combination appears warranted.
Despite recent advances in our understanding of melanoma, this is a disease without effective therapy (1) . We recently reported on a phase II trial of a novel topoisomerase (topo) I inhibitor, karenitecin (KTN), in metastatic melanoma (2) . Given the synergy between histone deacetylase (HDAC) inhibitors and other classes of antineoplastics (especially topo II inhibitors; ref. 3) , we examined if HDAC inhibition could potentiate the cytotoxicity and strand breakage caused by topo I inhibitors and if this combination could be tolerated and result in greater antitumor efficacy clinically.
HDAC inhibitors (HDACi) have emerged as an important class of agents for cancer therapy (4 -6) . These agents bind reversibly to the active site of HDAC (7), inhibiting it and causing histone hyperacetylation, chromatin decondensation, growth arrest, and differentiation (8 -10) . HDACi appear to be active as single agents in cutaneous T-cell lymphoma but not in common solid tumor malignancies (5) . HDACi can potentiate the cytotoxicity of topo II inhibitors (3, 11, 12) . The synergy appears to result from increased accessibility of DNA to topo inhibitors (3) . The synergy appears to be sequence specific (13) . Indeed, a recent phase I trial of the HDACi valproic acid (VPA) and epirubicin showed unexpected clinical efficacy in malignancies such as melanoma where previous trials have shown a lack of efficacy of anthracyclines (14) . HDACi can inhibit different isotypes of these enzymes, so vorinostat may be more selective to HDAC 1, whereas VPA may show selectivity for HDAC 2 (15) .
(Sigma-Aldrich), 2 mmol/L glutamine, and 50 units/mL penicillin and 50 Ag/mL streptomycin (Fisher Scientific). Cells were incubated in a humidified atmosphere with 5% CO 2 at 37jC.
Apoptosis assays. Apoptosis assays were carried out as described previously (16) . Briefly, log-phase cells were pretreated with 2 mmol/L VPA (A375 cells) or 5 mmol/L VPA (A2058, SK-Mel-5, and SK-Mel-28 cells) for 48 h followed by a 2 h treatment with KTN. Apoptosis was determined 24 h later. Cell nuclei were stained with 0.5 Ag/mL bisbenzimide (Hoechst 33258). Apoptosis was scored by the presence of nuclear chromatin condensation and DNA fragmentation and evaluated by fluorescence microscopy. Two hundred cells were counted per experiment in at least six different fields (apoptotic nuclei/all nuclei Â 100). For the sequence experiments, log-phase cells were pretreated, post-treated, or treated concurrently with 2 mmol/L VPA for 48 h and two doses of KTN for 2 h. Apoptosis was determined 24 h after KTN exposure for the pretreatment group or at the end of the VPA treatment for the post-treatment and concurrent VPA treatment groups.
Single-cell gel electrophoresis (COMET) assay. The alkaline COMET assay was done as described by the manufacturer (Trevigen) and as described previously to show single-and double-strand DNA breaks (3, 17 -19) . A375 melanoma cells were treated with 2 mmol/L VPA followed by 1.5 h incubation with 0, 10, 50, or 500 nmol/L KTN. Cells were harvested by trypsinization and washed with cold PBS. Cells (5 Â 10 3 ) were resuspended in 1% low-melting agarose (Bio-Rad) and layered on frosted glass slides. The slides were lysed (2.5 mol/L NaCl, 100 mmol/L EDTA, 10 mmol/L Tris-HCl, 1% sodium sarcosinate, 10% DMSO, 1% Triton X-100 containing 25 g/mL proteinase K) for 0.5 h at 4jC. The lysis buffer was removed, and the slides were washed four times with alkaline wash buffer [300 mmol/L NaOH, 1 mmol/L EDTA (pH 12.
2)]. COMET tails were induced by electrophoresis for 20 min at 25 V in alkaline wash buffer. Slides were reequilibrated in TBE buffer [90 mmol/L Tris-HCl, 90 mmol/L boric acid, 2 mmol/L EDTA (pH 8.0)] for 1 h and stained with SYBR Green (Molecular Probes). Fifty images per slide were acquired (Vysis) and analyzed using ImageQuant
Translational Relevance
The preclinical data and phase I/IIclinical trial described in this article explore the combination of a histone deacetylase inhibitor (HDACi) with a topoisomerase (topo) I inhibitor in melanoma.We show that HDACipretreatmentpotentiates topo I inhibitor cytotoxicity in melanoma. Combined HDACi and topo I inhibitor treatment leads to increased DNA breakage compared with topo I treatment alone.The HDACi valproic acid could be combined at an active dose with a full dose of the topo I inhibitor, karenitecin. Histone hyperacetylation was observed in peripheral blood mononuclear cells. The combination was well tolerated.This study shows that a HDACi/topo I combination, using the agents described, maintains dose intensity and results in HDAC inhibition. This combination could have application not only for chemotherapy refractory cancers such as melanoma but perhaps also for malignancies where topo I inhibitors are more active such as colon cancer or ovarian cancer. /L, creatinine levels <1.5 times the upper limit of normal, bilirubin and serum glutamic oxaloacetic transaminase (aspartate transaminase) <1.5 times the upper limit of normal]. Patients with uncontrolled brain metastases or a history of seizure, women who were pregnant or nursing, and patients on medications known to interact with VPA were excluded.
Study treatment. VPA (Depakote; Abbott Labs) was given orally in two divided doses for 5 days. KTN was infused over 1 h daily for 5 days beginning on day 3 of each 3-week cycle. VPA (mg/kg/d) and KTN (mg/m Log-phase A375 cells were treated with or without 2 mmol/L VPA followed by a 1.5 h incubation with 0, 10, 50, or 500 nmol/L KTN. DNA damage was detected by alkaline COMETassay (sample assay at the bottom).
Results from 50 images were plotted for each condition (top). Results of two-tailed t tests comparingVPA-treated and untreated cells. Treatment assessment. Baseline evaluations included history, physical examination, and complete blood count with differential, metabolic, hepatic, and renal function assessments. Because VPArelated pancreatitis has been reported, amylase and lipase levels were also checked. These tests were repeated weekly during the first two cycles and then once every 3 weeks in all succeeding cycles. A 12-lead ECG was done on day 1 of VPA treatment to rule out preexisting QT-prolongation. Somnolence and confusion were assessed according to Common Terminology Criteria for Adverse Events version 3 before and after VPA treatment via mini-mental status tests. Disease restaging was done every two cycles (6 weeks).
Pharmacokinetic studies. Samples for evaluation of VPA pharmacokinetics were collected before and 4 h after the morning dose immediately before KTN infusion on day 3 of cycle 1. Blood samples (5 mL) were collected in heparinized tubes, processed within 30 min after collection, and stored at -20jC. Total and free fraction drug concentrations for therapeutic monitoring of VPA were determined by Quest Diagnostics (Nichols Institute). Fluorescence polarization assaying was done by an Abbott TDxFLx instrument for free levels and by an Abbott AxSym for total levels. Free fractioned plasma for free VPA testing was obtained by using Amicon Centrifree filtration devices (Millipore). Calibration was linear from 1 to 150 Ag/mL for total VPA and from 2 to 25 Ag/mL for free VPA. Dilutions were made for all samples outside of these ranges as these have been validated previously. Inter-and intra-assay variability was <5% for both tests. Unknown sample concentrations were extrapolated from the regression analysis of the standard curves. 20  57  1  1  1  0  1  0  21  74  2  1  1  0  0  1  22  50  2  0  0  0  1  0  23  65  1  0  0  0  0  0  24  29  1  0  1  0  1  1  25  69  2  1  2  1  0  1  26  67  2  1  0  0  0  0  27  67  2  0  1  0  0  0  28  38  4  0  1  1  0  0  29  71  3  0  0  0  0  0  30  62  3  0  0  0  0  0  31  71  3  0  1  1  0  0  32  69  0  1  1  1  0  0  33  62  0  1  2  1  0  1  34  57  3  1  0  0  0  0  35  42  2  1  1  0  0  1  36  49  2  0  1 Research.
on July 31, 2017. © 2009 American Association for Cancer clincancerres.aacrjournals.org Downloaded from KTN concentrations were determined in plasma by high-performance liquid chromatography using a modification of the previously published method by Smith et al. (20) . Heparinized blood samples (7 mL) were obtained at 0, 1, 2, 4, 6, 24, 25, 48, 49, 72, 73, 96, 97, 100, 102, and 120 h after infusion. Samples were prepared using solid-phase extraction in a 96-well plate format. Varian solid-phase extraction C18 well plates were used with the Varian Captivac 96-well solid-phase extraction apparatus. Before extraction, all standards, controls, and unknowns were diluted 1:1 with 5% hydrochloric acid followed by the addition of the internal standard, topotecan. All solid-phase extraction steps were carried out with 200 AL volumes, except for elution, which was 120 AL. Wells were conditioned with methanol and water followed by the loading of the plasma sample. Wells were washed with water followed by 60% methanol in water. Elution was achieved with a mobile phase of 0.01 mol/L ammonium acetate and acetonitrile. The eluted solid-phase extraction samples were injected to an Agilent Technologies 1100 high-performance liquid chromatography system using the aforementioned mobile phase. Separation was carried out on a C18 column at a flow rate of 1.0 mL/min with a gradient profile starting at 60% acetonitrile, holding for 3 min, then increasing to 90% acetonitrile across 4 min, and then returning to 60% acetonitrile over 1 min with a total run time of 15 min. Fluorescence detection was monitored at an excitation wavelength of 370 nm and emission of 430 nm. The method is linear from 0.5 to 50 ng/mL. Inter-and intraassay variability was <6% and 12.3%, respectively, and the assay had a relative mean error of <10%. Unknown sample concentrations were extrapolated from the regression analysis of the standard curves. This methodology was tested and validated under current International Conference on Harmonization/Food and Drug Administration criteria according to the Guidance for Industry on Bioanalytical Method (21) .
Histone H4 and H3 acetylation. Peripheral blood mononuclear cells were isolated with Ficoll centrifugation (Ficoll-Paque; GE HealthCare). Mononuclear cells were lysed in SDS lysis buffer containing 2% SDS, 0.06 mol/L Tris (pH 6.8), and 10% glycerol. Protein (25 Ag) was separated by gel electrophoresis, and acetylated H3 and H4 histones were visualized using anti-acetylated histone H3 and H4 (Upstate Biotechnology; polyclonal, 1:2,000) by Western blot analysis as described previously (13) . GAPDH (Chemicon; monoclonal) was used as a loading control and also provided a standard for comparing signal from gel to gel. MCF-7 cells (25 Ag) treated with or without 2 mmol/L VPA for 48 h were used to standardize the H3 and H4 signal.
Statistical analyses. Descriptive statistics were used to summarize the study patients. Toxicity was graded by Common Terminology Criteria for Adverse Events version 3.0, and tumor response was defined by the Response and Evaluation Criteria in Solid Tumors criteria (22) . SPSS version 16 (SPSS) was used to plot Kaplan-Meier survival distributions.
Results
VPA and KTN combination in melanoma cell lines. Melanoma cell lines were treated with either KTN alone or both KTN and VPA. As shown in Fig. 1 , an increase in KTN-induced apoptosis was seen in A375 (13-fold), SK-Mel-5 (3-fold), A2075 (10-fold), and SK-Mel-28 (11-fold) when cells were pretreated with VPA compared with KTN alone. These results were essentially unchanged if vorinostat was used instead of VPA or topotecan was used instead of KTN (data not shown). In addition, we also performed clonogenic assays following KTN alone or VPA followed by KTN in the A375 cell lines. We found that the IC 50 for KTN alone was 2.95 mmol/L, whereas the IC 50 for combined VPA and KTN was 0.86 nmol/L KTN with 0.125 mmol/L VPA. We tested whether schedule was important with four conditions: KTN only, simultaneous VPA and KTN, VPA followed by KTN, or KTN followed by VPA. As shown in Supplementary Fig. S1 , pre-exposure with VPA and simultaneous treatment with both agents were more effective than post-exposure with VPA. Next, we evaluated if this combination was effective in animal xenografts. Female athymic mice with A375 xenografts were treated with saline, VPA, KTN, or VPA followed by KTN (Supplementary Fig. S2 ). Reduced tumor volume was seen in mice pretreated with VPA followed by KTN compared with the other treatments. Because the mechanism of action of KTN involves binding to DNA and causes single-strand breaks, we tested whether pretreatment with the HDACi could potentiate DNA breakage (Fig. 2) . In this experiment, pretreatment with either no VPA or 2 mmol/L VPA was followed by exposure to KTN in the alkaline COMET assay as reflected in the lengthened COMET moment (bottom) and by Fig. 3 . Pharmacokinetic profiles ofVPA and increases in histone acetylation.VPA total and free plasma levels are shown, with levels in Ag/mL depicted on the X axis and doses on theYaxis (top). Bottom, fold histone H4 or H3 expression is plotted on theYaxis in peripheral blood mononuclear cells plotted against VPA dose on the X axis. Patients. Thirty-nine enrolled patients participated in this trial. Thirty-seven patients were evaluable for toxicity and 33 patients were evaluable for response. Patient demographics and tumor characteristics are summarized in Table 1 . Most patients were previously treated with at least one chemotherapy regimen, and 28% of patients had failed two prior chemotherapy regimens. Sixty-one percent of patients had advanced stage IVC disease and 15% of patients had a prior history of central nervous system involvement.
Treatment administration and drug delivery. If no DLT was observed, a cohort was limited to 3 patients each. If a given patient received less than one complete cycle of treatment (for any reason, except drug-related toxicity), that patient was replaced. Toxicities experienced in the first cycle are described in Table 2 .
DLT and other toxicities. We started with a VPA dose of 30 mg/kg/d for 5 days and escalated VPA to 60 mg/kg/d for 5 days, with KTN at 0.8 mg/m 2 /d. We then escalated KTN to 1.0 mg/m 2 /d for 5 days and continued escalating VPA to 90 mg/kg/d. We observed DLT at this VPA dose in 2 patients on cohort 5 (Table 2 ). Both patients experienced grade 3 neurologic toxicity (somnolence and confusion), which was transient. We deescalated to 60 mg/kg/d VPA and again observed no neurologic DLT. We then reescalated to 75 mg/kg/d VPA, and no DLT were seen at this level; this cohort was considered the maximum tolerated dose and was expanded to a total of 15 evaluable patients. Toxicities for the dose expansion cohort (Table 2) included grade 3 and 4 hematologic toxicities (4 absolute neutrophil count grade 4 and 5 absolute neutrophil count grade 3) and grade 1 and 2 neurologic toxicities (reversible somnolence: 11 with grade 2 and 5 with grade 1).
Response. The best response seen was prolonged stable disease, up to 50 weeks. Stable disease was seen in 39% (13 of 33) of evaluable patients and in all cohorts, including cohort 1 (Supplementary Fig. S3 ). The median time to progression and overall survival of the entire trial population were 8.9 weeks (confidence interval, 5.7-12.1) and 31.8 weeks (confidence interval, 19.8-43.8), respectively. In the dose expansion cohort, 47% (7 of 15) of evaluable patients had stable disease, and median time to progression was 10.3 weeks (confidence interval, 5.3-14.7); the median overall survival was 32.9 weeks (confidence interval, 9.3-54).
Pharmacokinetic results. We profiled VPA levels on day 3, just before the first KTN infusion. Total and free VPA levels increased linearly with VPA dose (Fig. 3, top) . At maximum tolerated dose (75 mg/kg/d VPA), the median level of VPA was 184 Ag/mL (1.27 mmol/L VPA). We also examined the pharmacokinetics of KTN with and without VPA in the first 10 patients. No significant differences were seen (data not shown). We examined KTN concentration-time profiles as shown in Fig. 4A and Supplementary Table S1 for the fifth KTN dose period in combination with VPA. The data for first dose period produced similar profiles (data not shown). The mean C max for the first five doses of KTN in combination with VPA is represented in Fig. 4B The terminal half-life for the fifth dose (n = 6) was calculated at 11.0 F 1.9 h, and the clearance was determined to be 37.0 F 17.3 L/h. The concentration-time profile and AUC of KTN showed limited variation within each dose level of KTN regardless of the dose of VPA, suggesting that the escalating doses of VPA had little effect on the pharmacokinetics of KTN (mean AUC of KTN as a single agent was 87.1 F 52 and 73.8 F 32 when combined with VPA).
Histone acetylation: pharmacodynamic studies. Peripheral blood mononuclear cells pre-VPA and day 3 post-VPA were isolated and acetyl histone H3 or H4 was determined. As shown in Fig. 3 (bottom) , there appears to be increased histone H4 and H3 hyperacetylation with an apparent plateau at 60 mg/kg/d VPA. It should be noted that only 1 patient was sampled at 90 mg/kg/d and no patients were sampled at 30 mg/kg/d. 
Discussion
Current therapy for metastatic melanoma remains highly unsatisfactory. Standard first-line dacarbazine chemotherapy in metastatic melanoma is associated with a median progression-free survival of only 6 to 8 weeks and median overall survival of only 5.6 to 7 months in phase III clinical trials (23 -26) . Combinations or variations of existing chemotherapy or biotherapy agents have not appreciably improved clinical outcomes (23, 24, 26 -28) . The introduction of novel non-cross-resistant drugs combinations is therefore vital to improve outcomes for the vast majority of patients who progress on front-line chemotherapy.
We have shown previously that KTN, a novel topo I inhibitor, has a moderate degree of activity in melanoma (2) with prolonged stable disease seen in 33% of patients. We asked if HDAC inhibition, which can cause chromosomal decondensation and increased sensitivity to topo II inhibitors (3, 13, 16, 29) , may do the same with topo I inhibitors. We determined the effects of dose and sequence of treatment in a series of preclinical studies ( Figs. 1 and 2 ; Supplementary Figs. S1 and S2). We found that if HDACi pretreatment was followed by topo I inhibitor, increased apoptosis was seen in multiple melanoma cell lines. This increased cytotoxicity was schedule specific and required HDACi pretreatment and was associated with increased DNA strand breaks, apoptosis, and reduced tumor growth in xenografts. It should be noted that the doses of KTN used in the preclinical experiments were sometimes substantially larger depending on the assay used than the actual KTN concentrations achieved in humans (Figs. 1, 2, and 4; Supplementary Figs. 1 and 2; Supplementary Table S1) . Also, the apoptosis assays predominantly used in the preclinical studies ( Fig. 1; Supplementary Fig. S1 ) reflect cell death and measure only one aspect of chemotherapy response and other types of assays (such as clonogenic assays or metabolic assays) can reflect other important aspects of response to chemotherapy. Based on these preclinical results, we conducted a phase I/II trial of the HDACi VPA plus KTN in melanoma.
This combination was well tolerated, and toxicities were largely as expected and nonoverlapping ( Table 2 ). The maximum tolerated dose was 75 mg/kg/d VPA for 5 days with 1 mg/m 2 /d KTN ( Table 2) . We subsequently expanded this cohort and accrued 19 patients at this level, of whom 15 were evaluable for both toxicity and response. Based on results from this trial, we would recommend VPA at this dose if a 5-day continuous administration is being considered in other oncology trials.
The best response seen in this trial was stable disease (similar to the previous KTN phase II trial in melanoma; Supplementary  Fig. S3) ; however, this was seen in almost half of evaluable patients. The median overall survival was 32.9 weeks with a median progression-free survival of 10.3 weeks in the dose expansion cohort. These results, albeit in the context of a singleinstitution phase I/II trial, compare favorably with recent trial data in melanoma, considering that the vast majority of patients in this trial had previously progressed on chemotherapy and had M 1c disease. In this trial, 7 of 15 (47%) patients had stable disease with median progression-free survival of 10.3 weeks versus 34% with stable disease with median progression-free survival of 7.9 weeks shown in patients on the previous single-agent KTN phase II study.
In conclusion, the addition of HDACi VPA appears to be a promising modality to increase sensitivity to topo I inhibition in preclinical models in melanoma and is tolerable in vivo with disease stabilization occurring in nearly half of treated patients at maximum tolerated dose. Clearly, these data need to be tested in randomized trials to determine whether there is indeed increased efficacy compared with current standard treatments. Although our preclinical and clinical trial data relate to this combination in melanoma, other diseases such as colon or ovarian cancer, where topo I inhibitors are better established, may be even more responsive to this combination. 
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